On January 5, 2024, Camac Partners LLC announced that it believed that the allegations set forth in the Texas Action by Forte Biosciences Inc are baseless, without merit and subject to immediate dismissal, this filing is being made solely to moot the Company?s claims in the Texas Action relating to alleged disclosures and omissions, and Camac Partners specifically deny all allegations in the Texas Action, including, without limitation, that any additional disclosures were or are required as to any of the defendants in the Texas Action, Camac Partners mentioned that it intend to defend themselves vigorously and will pursue all available rights and remedies. In addition, Camac Partners stated that On January 3, 2024, it agreed to indemnify its nominees Michael Hacke and Chris McIntrye related to the Texas Action.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.7163 USD | -3.07% | -2.41% | -12.83% |
Mar. 18 | Forte Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Jan. 05 | Camac Partners Provides Information to Shareholders | CI |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-12.83% | 26.07M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- FBRX Stock
- News Forte Biosciences, Inc.
- Camac Partners Provides Information to Shareholders